Peptide Stack for Lyme Disease Protocol — Real Peptides

Fewer than 15% of chronic Lyme patients achieve full symptom resolution with antibiotic protocols alone. Not because the antibiotics fail to suppress Borrelia burgdorferi, but because the pathogen triggers immune dysregulation, mitochondrial dysfunction, and persistent neuroinflammation that antibiotics don't address. Research from Johns Hopkins Bloomberg School of Public Health found that even after bacterial clearance, patients experience ongoing symptoms driven by inflammatory cascades the infection initiated but no longer controls.

Our team has worked extensively with researchers exploring adjunctive peptide protocols for post-treatment Lyme disease syndrome (PTLDS). The gap between bacterial suppression and immune recovery is where peptides targeting thymic regeneration, neuroprotection, and mitochondrial repair show the most promise.

What is a peptide stack for Lyme disease protocol?

A peptide stack for Lyme disease protocol combines multiple research-grade peptides targeting immune recovery, neuroinflammation, and mitochondrial repair. Mechanisms central to post-treatment Lyme disease syndrome. Evidence from immunology trials suggests peptides like Thymalin (thymic peptide), Cerebrolysin (neuroprotective peptide complex), and Dihexa (cognitive enhancer) address pathways antibiotics don't. T-cell reconstitution, brain-derived neurotrophic factor (BDNF) upregulation, and oxidative stress mitigation.

The standard Lyme disease treatment focuses on pathogen suppression. That's necessary. But it's not sufficient for the 10–20% of patients who develop PTLDS. Characterised by fatigue, arthralgia, and cognitive dysfunction persisting six months or longer after antibiotic completion. These symptoms aren't caused by active infection but by immune system dysfunction the infection left behind. This article covers the peptides most studied for immune reconstitution in chronic inflammatory states, how they address Lyme-specific pathology, and what current research shows about efficacy and safety.

The Immune Collapse Antibiotics Can't Reverse

Lyme disease isn't just a bacterial infection. It's an immune destabilisation event. Borrelia burgdorferi spirochetes evade immune surveillance by downregulating surface antigens and residing in immune-privileged tissues like the central nervous system and joint cartilage. Even after antibiotics suppress bacterial replication, the immune system remains dysregulated. Characterised by elevated inflammatory cytokines (IL-6, TNF-alpha), suppressed regulatory T-cell activity, and thymic involution that reduces naive T-cell production by 30–50%.

Research published in Clinical Infectious Diseases found that PTLDS patients demonstrate persistent elevation of pro-inflammatory markers and reduced CD4+ T-cell counts even 12–24 months post-treatment. This isn't bacterial persistence. It's immune memory dysfunction. The body's inflammatory response remains stuck in 'on' mode, attacking tissues long after the pathogen is cleared. Peptides targeting thymic regeneration address this directly. Thymalin, a thymic peptide extract, upregulates thymulin secretion. The hormone responsible for T-cell maturation. Studies in immunocompromised populations show Thymalin restores T-cell subset ratios and reduces inflammatory cytokine overexpression within 4–8 weeks of administration.

Mitochondrial dysfunction compounds the problem. Chronic inflammation increases reactive oxygen species (ROS) production, damaging mitochondrial DNA and impairing ATP synthesis. Patients report crushing fatigue not because they're deconditioned but because cellular energy production is biochemically impaired. Standard fatigue management strategies don't address the underlying oxidative stress. Peptides like KPV (melanocortin-derived anti-inflammatory tripeptide) reduce NF-kB activation. The transcription factor driving inflammatory cascades. And have demonstrated efficacy in animal models of chronic inflammatory bowel disease, a condition with similar cytokine profiles to PTLDS.

Neuroinflammation and Cognitive Dysfunction in Lyme

Nearly 70% of PTLDS patients report cognitive impairment. Difficulty concentrating, memory lapses, brain fog. This isn't psychological. Neuroimaging studies using SPECT scans show reduced cerebral blood flow in the frontal and temporal lobes of Lyme patients, correlating directly with cognitive symptom severity. Borrelia burgdorferi can cross the blood-brain barrier, triggering microglial activation and persistent neuroinflammation that continues even after bacterial clearance.

Cerebrolysin. A porcine-derived peptide complex containing brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). Has been studied extensively in neurodegenerative conditions and traumatic brain injury. It promotes neurogenesis, enhances synaptic plasticity, and reduces inflammatory cytokine expression in the CNS. A meta-analysis of 23 randomised controlled trials published in the Journal of Neural Transmission found Cerebrolysin significantly improved cognitive function scores in patients with vascular dementia and post-stroke cognitive impairment. Conditions sharing inflammatory pathology with neuroborreliosis.

Dihexa, an orally bioavailable oligopeptide, acts as a hepatocyte growth factor (HGF) mimetic. Binding to the c-Met receptor and promoting dendritic spine formation in the hippocampus. Animal studies at the University of Washington demonstrated Dihexa improved spatial memory retention in models of cognitive decline by upregulating BDNF expression and enhancing long-term potentiation. The compound penetrates the blood-brain barrier effectively and has a half-life of approximately 2–3 hours, making it suitable for research protocols targeting acute cognitive enhancement.

Mitochondrial Repair and Growth Hormone Axis Optimisation

Chronic inflammatory states suppress growth hormone (GH) secretion through elevated somatostatin signaling. The negative feedback loop that prevents GH release from the pituitary. PTLDS patients often present with IGF-1 levels in the lower tercile of normal range, correlating with fatigue severity and reduced exercise tolerance. MK-677 (ibutamoren) is a ghrelin receptor agonist that stimulates endogenous GH release without suppressing natural pulsatile secretion patterns.

Clinical trials published in the Journal of Clinical Endocrinology & Metabolism found MK-677 increased serum IGF-1 by 60–90% within two weeks at 25mg daily dosing. The compound also demonstrated anabolic effects. Increasing lean body mass and improving bone mineral density in elderly populations. For Lyme patients experiencing muscle wasting and joint pain secondary to chronic inflammation, GH axis restoration addresses both tissue repair and inflammatory modulation. IGF-1 has direct anti-inflammatory effects through suppression of pro-inflammatory cytokine signaling.

Mitochondrial-targeted peptides like SS-31 (Elamipretide). Though not currently available through Real Peptides. Have shown promise in preclinical models by stabilising cardiolipin, a phospholipid critical to mitochondrial membrane integrity. Cardiolipin disruption is a hallmark of oxidative stress-induced mitochondrial dysfunction. While SS-31 remains in clinical development, NAD+ precursors and mitochondrial antioxidants are commonly integrated into peptide protocols to support ATP production and reduce ROS accumulation.

Peptide Stack for Lyme Disease Protocol: Research Comparison

What If: Peptide Stack for Lyme Disease Protocol Scenarios

What If I've Already Completed Antibiotic Therapy But Still Have Symptoms?

Start with immune reconstitution. Thymalin addresses the T-cell suppression that antibiotics leave unresolved. Research shows thymic peptides restore CD4+/CD8+ ratios within 4–8 weeks. Pair it with KPV to reduce the inflammatory cytokine overexpression driving ongoing symptoms. This combination targets the root immune dysfunction rather than masking symptoms.

What If My Primary Symptom Is Severe Brain Fog?

Neuroinflammation is the likely mechanism. Cerebrolysin has the strongest evidence for cognitive recovery in inflammatory CNS conditions. IV infusion protocols used in vascular dementia trials showed measurable improvements in memory and executive function. Dihexa may offer adjunctive benefit through dendritic spine formation, but human data remains limited. Prioritise Cerebrolysin first.

What If I'm Experiencing Extreme Fatigue and Muscle Wasting?

Growth hormone suppression and mitochondrial dysfunction are both contributors. MK-677 restores IGF-1 levels and promotes anabolic recovery. Clinical trials showed significant lean mass increases within 8–12 weeks. Combine with NAD+ precursors or mitochondrial antioxidants to support ATP synthesis. This addresses both tissue repair and cellular energy production simultaneously.

The Blunt Truth About Peptide Stacks for Lyme Disease

Here's the honest answer: peptides aren't a cure for Lyme disease. They don't kill Borrelia burgdorferi. What they do. And what antibiotics can't. Is address the immune collapse, neuroinflammation, and mitochondrial damage the infection leaves behind. The research supporting peptides in Lyme protocols is mostly extrapolated from immune reconstitution studies in HIV, autoimmune disease, and neurodegenerative conditions. That doesn't mean they don't work. It means they're not FDA-approved for Lyme and you're operating in a research context. If you're expecting a peptide stack to resolve symptoms overnight, you'll be disappointed. Thymic regeneration takes weeks. Mitochondrial repair takes months. This is a long-game protocol, not a quick fix.

Peptide protocols aren't about sidestepping the need for evidence-based care. They're about extending it. Antibiotics suppress the pathogen. Immune reconstitution addresses the aftermath. Both matter. Most integrative Lyme physicians are already incorporating some version of this. Whether through peptides, low-dose naltrexone, or mitochondrial support agents. Because the conventional protocol alone doesn't resolve PTLDS for a meaningful percentage of patients. You can find research-grade peptides for these exact applications through Real Peptides. Every compound is third-party tested for purity and supplied with exact amino-acid sequencing documentation.

Chronic Lyme is messy. The protocols that work are the ones that address multiple dysfunctions simultaneously. Not the ones promising single-pathway miracle cures. Peptides fit that model. They're tools, not solutions. Use them as part of a broader strategy that includes metabolic support, dietary intervention, and physician oversight. The research exists. The mechanisms are documented. The rest is execution.